Aquis Stock Exchange Weekly Highlights 1/9/23
0
Published:
September 1, 2023
Most recent
Marula Mining provided an update on the Blesberg Lithium and Tantalum Mine (“Blesberg”), where the Company through arrangements with Q Global Commodities ("Q Global") is completing the acquisition of two sensor-based, XRF ore sorting plants that will now be commissioned at Blesberg in Q4 2023 and used initially to increase the production of high-grade spodumene ore from the processing of the historical stockpiles. Read more…
The company also announced that it has signed a contract for an initial trial shipment of high-grade lithium ore from Blesberg with a Chinese importer and exporter of metalliferous ores. The agreement has been signed for an initial sale of 27.5 tonnes of high-grade material processed from the historic stockpiles at Blesberg, at a sales price of US$3,000 per tonne. Read more…
The company also announced that it has signed a contract for an initial trial shipment of high-grade lithium ore from Blesberg with a Chinese importer and exporter of metalliferous ores. The agreement has been signed for an initial sale of 27.5 tonnes of high-grade material processed from the historic stockpiles at Blesberg, at a sales price of US$3,000 per tonne. Read more…
Ananda Developments provided a corporate update.
Highlights:
Highlights:
• The Chief Scientist Office, responsible for funding research in NHS Scotland, has been confirmed as the funder of the endometriosis randomised controlled trial ("RCT") using MRX1.
• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.
• Medical cannabis plant cultivation trials complete.
• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.
• Medical cannabis plant cultivation trials complete.
• Medical cannabis genetic breeding programme reached third generation of plants. Breeding protocol fully established.
• MRX1 and MRX2 cannabidiol medicines available for sale via UK based specials pharmacies.
Ananda's CEO, Melissa Sturgess, commented: "The response to the announcement earlier this month that the endometriosis trial is being funded by NHS Scotland has been extraordinarily encouraging. Suddenly, we are experiencing awareness that a cannabinoid medicine has the potential to be a mainstream licenced medicine for this condition which affects more than 190 million women globally.”
• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.
• Medical cannabis plant cultivation trials complete.
• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.
• Medical cannabis plant cultivation trials complete.
• Medical cannabis genetic breeding programme reached third generation of plants. Breeding protocol fully established.
• MRX1 and MRX2 cannabidiol medicines available for sale via UK based specials pharmacies.
Ananda's CEO, Melissa Sturgess, commented: "The response to the announcement earlier this month that the endometriosis trial is being funded by NHS Scotland has been extraordinarily encouraging. Suddenly, we are experiencing awareness that a cannabinoid medicine has the potential to be a mainstream licenced medicine for this condition which affects more than 190 million women globally.”
Unigel Group plc announced its unaudited half-year results for the period ended 30 June 2023. Comparative data is for the post-acquisition six-month period ended 31 December 2022.
Financial highlights:
• Revenue of £17.95m (£18.83m)
• Gross profit of £2.39m with a gross profit margin of 13.3% (£2.23m and 11.8%)
• Revenue of £17.95m (£18.83m)
• Gross profit of £2.39m with a gross profit margin of 13.3% (£2.23m and 11.8%)
• Profit after tax of £0.63m (£0.32m)
• Final dividend of 2.5p per share distributed post period end in July 2023
• Gross profit of £2.39m with a gross profit margin of 13.3% (£2.23m and 11.8%)
• Revenue of £17.95m (£18.83m)
• Gross profit of £2.39m with a gross profit margin of 13.3% (£2.23m and 11.8%)
• Profit after tax of £0.63m (£0.32m)
• Final dividend of 2.5p per share distributed post period end in July 2023
Operational highlights
• New customer acquisitions in both steel tape and thixotropic gel businesses
• De-risking and diversifying raw material sourcing base
• Cost improvement in logistics and material handling activities
• Operating cost improvement through optimisation of production staff and administrative resources
• De-risking and diversifying raw material sourcing base
• Cost improvement in logistics and material handling activities
• Operating cost improvement through optimisation of production staff and administrative resources
